ARGX-115, an antibody targeting to inhibit the release of TGF-beta from regulatory T-cells in an innovative way, reaches its first preclinical milestone. This triggers a $10 million payment from development partner AbbVie.

argenx starts a new phase II clinical trial with ARGX-110, a SIMPLE antibody targeting CD70. ARGX-110 will be evaluated as a monotherapy for relapsed/refractory cutaneous T-cell lymphoma (CTCL).

MDxHealth today announced BJU International published a study demonstrating that its SelectMDx for Prostate Cancer test can reduce overdiagnosis and overtreatment of men at risk of prostate cancer versus PSA testing alone, leading to a reduction in total cost per patient and a quality of life improvement.

First dosing triggers $10 million milestone payment from Gilead

VIB-UGent researchers unravel the functioning of what is believed to be the master protein that drives a range of allergic diseases, TSLP. These insight allowed the researchers to develop a first protein-based inhibitor of TSLP.

Although ASIT's drug against house dust mite allergy has proven to be safe, little clinical efficacy has been detected.

The japanese pharma enterprise Astellas has come to an agreement with Belgian biotech Ogeda, specialised in the development of small molecules targeting GPCR's.

Galapagos, together with partner Gilead, sets out to expand the applicability of its flagship molecule Filgotinib. Three new phase II trials are initiated to assess the effect of Filgotinib in Sjögren’s syndrome, ankylosing spondylitis and psoriatic arthritis.

Biocartis opens doors in the US and appoints US General Manager Vishal Sikri to delegate outrol of Idylla in the states.

MDx Health and Ghent University have signed licensing and collaboration agreements for the development of biomarker visualisation technology in prostate and bladder cancer.

The BioBase4SME project, co-financed by Europe’s Interreg NWE programme, is now providing start-up companies working in the bioeconomy with €7,000 worth of specialist training, fully funded by the project. An intensive, week-long Innovation Biocamp will give these companies the tools they need to commercialise their idea and grow their company. The training culminates in a live pitch to investors.

Kiadis Pharma N.V., a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that the Pediatric Committee (PDCO) of the European Medicines Agency (EMA) has accepted the Company’s Pediatric Investigation Plan (PIP) for ATIR101™ for the adjunctive treatment in hematopoietic stem cell transplantation (HSCT) for a malignant disease. In addition, the PDCO has agreed that the Company may defer conducting the studies defined in the PIP until after it files a Marketing Authorization Application (MAA) in Europe for the use of ATIR101™ for the treatment of blood cancers.

VIB and DNAlytics are proud to announce their partnership to develop a data-driven, high-performance and non-invasive Colorectal Cancer screening test, the ColonoKit. Colorectal cancer is the third most common form of cancer globally and the second most common cause of cancer deaths. The chance of a cure is high if the cancer is detected early enough, but early detection is not a given. Based on a research program from VIB, KU Leuven and UZ Leuven, with the support of the Fournier Majoie Foundation, DNAlytics will develop the ColonoKit which should make it possible to detect colorectal cancer in an early stage using a simple blood test.